Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

McKinsey
Merck
Moodys
Dow
McKesson
Colorcon

Last Updated: December 7, 2019

DrugPatentWatch Database Preview

Patent: 10,111,968

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 10,111,968
Title:Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein
Abstract: The present invention relates to a nucleic add sequence, comprising or coding for a coding region, encoding at least one peptide or protein comprising a therapeutic protein or a fragment, variant or derivative thereof, at least one histone stem-loop and a poly(A) sequence or a polyadenylation signal. Furthermore the present invention provides the use of the nucleic add for increasing the expression of the encoded peptide or protein, particularly for the use in gene therapy. It also discloses its use for the preparation of a pharmaceutical composition, e.g., for use in gene therapy, particularly in the treatment of diseases which are in need of a treatment with a therapeutic peptide or protein, preferably as defined herein. The present invention further describes a method for increasing the expression of a peptide or protein comprising a therapeutic protein or a fragment, variant or derivative thereof, using the nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal.
Inventor(s): Thess; Andreas (Kusterdingen, DE), Schlake; Thomas (Gundelfingen, DE), Probst; Jochen (Wolfschlugen, DE)
Assignee: CureVac AG (Tubingen, DE)
Application Number:15/233,933
Patent Claims:see list of patent claims

Details for Patent 10,111,968

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Glaxosmithkline NUCALA mepolizumab INJECTABLE;SUBCUTANEOUS 761122 001 2019-06-06   Start Trial CureVac AG (Tubingen, DE) 2032-02-15 RX search
Genentech Inc HERCEPTIN HYLECTA trastuzumab; hyaluronidase-oysk INJECTABLE;SUBCUTANEOUS 761106 001 2019-02-28   Start Trial CureVac AG (Tubingen, DE) 2032-02-15 RX search
Astrazeneca Ab FASENRA benralizumab INJECTABLE;INJECTION 761070 001 2017-11-14   Start Trial CureVac AG (Tubingen, DE) 2032-02-15 RX search
Genentech Inc RITUXAN HYCELA rituximab; hyaluronidase (human recombinant) SOLUTION;SUBCUTANEOUS 761064 002 2017-06-22   Start Trial CureVac AG (Tubingen, DE) 2032-02-15 RX Orphan search
Genentech Inc RITUXAN HYCELA rituximab; hyaluronidase (human recombinant) SOLUTION;SUBCUTANEOUS 761064 001 2017-06-22   Start Trial CureVac AG (Tubingen, DE) 2032-02-15 RX Orphan search
Wyeth Pharms Inc MYLOTARG gemtuzumab ozogamicin VIAL;SINGLE-DOSE 761060 001 2018-04-09   Start Trial CureVac AG (Tubingen, DE) 2032-02-15 RX Orphan search
Genentech Inc OCREVUS ocrelizumab INJECTABLE;INJECTION 761053 001 2017-03-28   Start Trial CureVac AG (Tubingen, DE) 2032-02-15 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

International Patent Family for US Patent 10,111,968

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Harvard Business School
Express Scripts
Johnson and Johnson
Dow
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.